Newpath Partners

Newpath Partners is a Boston-based venture capital firm specializing in life sciences. Founded in 2018 by Dr. Thomas Cahill, Newpath focuses on building biotechnology companies from the ground up, partnering with leading academic scientists to translate groundbreaking scientific discoveries into transformative therapies. With a strong commitment to high-impact ventures, the firm is particularly known for its deep involvement in the early stages of company formation, often acting as a founding investor. Newpath Partners manages multiple funds, with its second fund, raised in 2021, amounting to $350 million. This fund continues Newpath’s mission to back companies with high scientific originality and ambitious goals, particularly in areas like regenerative medicine, genomics, and oncology. The firm typically invests in early-stage ventures, providing not only capital but also strategic guidance and access to a network of industry leaders. Dr. Cahill, who also founded the nonprofit Scientists to Stop COVID-19, leads a team that is highly experienced in both science and business, ensuring that the companies they back are well-positioned to make a significant impact in the life sciences arena. Newpath’s approach is characterized by a close collaboration with founders, aligning interests across scientists, investors, and management teams to drive innovation and success.